ERC Advanced Grants allow exceptional established research leaders to pursue ground-breaking, high-risk projects that open new directions in their respective research fields or other domains. They have been awarded for the fourth time this year. 2284 applications were submitted following the last call.
The grant will fund a project entitled "Transcriptional networks controlling lymphocyte development", or “LymphoControl” in short. The aim of the project is to elucidate how transcription factors regulate the development of B- and T-lymphocytes. These white blood cells are the main players in the body’s adaptive immune system.
They are derived from stem cells in the bone marrow and undergo several stages of differentiation before becoming fully functional, mature lymphocytes of the B- or T-cell lineage. Transcription factors are regulatory proteins encoded in the genome that control key stages in this process. Deregulation of the transcriptional control can severely disrupt the programmed cell fate and cause certain types of blood cancer.
Meinrad Busslinger has a long record in immunological research. He was the first to identify a critical factor, named Pax-5, which activates a B cell specific program in the precursor cells and suppresses alternative pathways. Pax-5 is also involved in the development of acute lymphoblastic leukemia in humans.
The project “LymphoControl” will build on previous research efforts, such as the creation of transgenic mice that carry molecular “tags” at the ends of transcription factors.
Busslinger is excited about the European commitment to basic research: “The ERC grant will allow us to carry out a project which requires massive human and technical resources. We have already established the required know-how and infrastructure, owing to the Austrian Science Fund and our sponsor Boehringer Ingelheim. Now we can really take full advantage of the exceptional facilities at the IMP.” The grant will also open career-paths for young researchers. Six additional scientists will be employed under the ERC-funded project.
Meinrad Busslinger was born in Switzerland in 1952. He studied Biochemistry at the ETH Zurich and obtained a doctorate in molecular biology from the University of Zurich. Following postdoctoral studies at the MRC Institute Mill Hill, London, he became a group leader at the University of Zurich. In 1987, he followed Max Birnstiel to the newly founded Research Institute of Molecular Pathology (IMP) in Vienna.
Busslinger is a Senior Scientist and Director of Academic Affairs at the IMP, Professor at the University of Vienna and a full member of the Austrian Academy of Sciences and of the European Molecular Biology Organisation EMBO. He has published over 130 papers in peer-reviewed journals and serves on the editorial boards of several scientific journals. Busslinger was awarded the Wittgenstein prize of the Austrian government in 2001 and the Virchow Medal by the University of Würzburg in 2010.
The recent allocation raises the number of ERC Grants awarded to IMP faculty to six: Barry Dickson succeeded in securing an advanced grant in the first round of evaluations in 2008. Stefan Westermann, Alexander Stark, Andrew Straw and Manuel Zimmer received ERC Starting Grants.
The Research Institute for Molecular Pathology carries out basic biomedical research in Vienna, Austria. Its main sponsor is Boehringer Ingelheim. Some 200 researchers from over 30 countries study life at molecular and cellular levels, information processing and storage in neural circuits, mechanisms of development and disease and interdisciplinary topics. The aim is a thorough understanding of complex biological processes that could lead to the development of new therapeutic concepts.Contact:
Dr. Heidemarie Hurtl | idw
Further reports about: > Advanced Investigator Grant > Boehringer > ERC Advanced Grants > ERC Starting Grant > European Molecular Biology > IMP > LymphoControl > Molecular Target > Pathology > Senior Citizens > biological process > blood cell > immune cells > lymphocyte development > transcription factor > white blood cell
The quest for the oldest ice on Earth
14.11.2016 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung
Empa Innovation Award for new flame retardant
09.11.2016 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering